Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects

Completed · Phase 1

Conditions studied: Allergic Rhinitis

In brief

This study will evaluate the safety and tolerability of single and multiple doses of VAK694 in healthy volunteers and otherwise healthy volunteers with a history of allergies.

Key facts

Study ID

NCT00620230

Run by

Novartis

People needed

46

Starts

2007-10-01

Expected to finish

2008-04-01

Last updated by the study team

2010-09-27

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• History of allergic rhinitis (Part 2 only)

You may not qualify if…

• Very low or high body weight
• Heavy or recent smoker
• Exposure to human monoclonal antibodies
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Novartis Investigator Site — North Miami Beach, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.